AlphaCrest Capital Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-10,972
Closed -$434K 496
2022
Q3
$434K Sell
10,972
-32,759
-75% -$1.45M 0.03% 1028
2022
Q2
$1.92M Buy
43,731
+18,714
+75% +$809K 0.09% 329
2022
Q1
$998K Sell
25,017
-13,979
-36% -$498K 0.06% 545
2021
Q4
$1.57M Sell
38,996
-13,549
-26% -$506K 0.06% 572
2021
Q3
$2.14M Buy
52,545
+27,368
+109% +$1.14M 0.11% 276
2021
Q2
$1.14M Buy
25,177
+4,984
+25% +$221K 0.05% 596
2021
Q1
$842K Buy
20,193
+4,801
+31% +$219K 0.05% 570
2020
Q4
$657K Buy
15,392
+3,197
+26% +$115K 0.05% 500
2020
Q3
$320K Buy
+12,195
New +$340K 0.03% 826
2019
Q4
Sell
-26,100
Closed -$405K 1296
2019
Q3
$405K Buy
26,100
+7,600
+41% +$125K 0.02% 1011
2019
Q2
$318K Sell
18,500
-34,000
-65% -$549K 0.03% 846
2019
Q1
$845K Buy
+52,500
New +$851K 0.13% 256

Other funds holding HALO

AlphaCrest Capital Management's HALO Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Halozyme (HALO) in Q4 2022, closing a stake of 10,972 shares — an estimated $434K sold.

AlphaCrest Capital Management first reported a position in HALO in Q1 2019 and held it in 12 quarters. The position peaked at $2.14M in Q3 2021. 423 funds tracked by Wall St. Rank hold HALO as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Halozyme position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 10,972 Halozyme shares in Q4 2022, an estimated $434K.
  • AlphaCrest Capital Management first reported a position in Halozyme in Q1 2019 and held it in 12 quarters.
  • AlphaCrest Capital Management's Halozyme position peaked at $2.14M in Q3 2021.
  • 423 funds tracked by Wall St. Rank held Halozyme as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.